American Oriental Bioengineering, Inc. Common Stock Approved for Listing on the Archipelago Exchange.

HONG KONG -- American Oriental Bioengineering, Inc. (AMEX:AOB), an emerging Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that its common stock has been approved for listing on the Archipelago Exchange (ArcaEx), a facility of the Pacific Exchange, under the symbol AOB. The Company anticipates that its common stock will commence trading on ArcaEx on November 11, 2005.

"We are pleased to bring this extra level of liquidity to our shareholders, and additional exposure to potential investors," said Tony (Shujun) Liu, the Company's Chief Executive Officer.

In addition to being listed on ArcaEx, the Company's common stock will continue to be listed on the American Stock Exchange under the symbol AOB.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. (AOBO) is a leading Chinese biotechnology company that uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. The Company also produces Cease-Enuresis Soft Gel, the only Chinese FDA-approved first grade, prescription medicine that is specially formulated to help alleviate bed-wetting and incontinence. The Company is a leading producer of products in both the nutriceuticals and pharmaceuticals areas in China. For more information, visit http://www.bioaobo.com.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.